



## BIOHARVEST SCIENCES INC. ANNOUNCES RESIGNATION OF LIRON CARMEL

Vancouver, BC / January 10, 2022 / BioHarvest Sciences Inc. (the “Company”, “BioHarvest”) (CSE: BHSC) announces today that Liron Carmel has resigned as a member of the Company’s Board of Directors.

Dr. Zaki Rakib, Chairman of the board, said “*on behalf of the board of directors, I want to thank Liron for his contribution to the governance of BioHarvest during his service on the board. As announced when Mr. David Tsur joined the board in October 2021, the Company will continue to enhance the board with members bringing expertise in Biotech*”.

### About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: [www.bioharvest.com](http://www.bioharvest.com).

### BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

### For further information, please contact:

Dave Ryan, VP Investor Relations & Director

Phone: 1 (604) 622-1186

Email: [dave@bioharvest.com](mailto:dave@bioharvest.com)



### Forward-Looking Statements

*Information set forth in this news release includes forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives. Obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. The timetable of development announcements on new Superfruit Nutraceuticals products is uncertain and depends on factors such as availability of time of scientific staff and facilities and results of testing all of which is subject to uncertainty; 2021 projections are based on management’s best estimate but cannot be assured as customer preferences and other factors may not occur as anticipated and are subject to risk.*

*All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.*

**Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.**